|
1
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
Classification of Tumors of the Central Nervous System: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Report of brain tumor registry of Japan
(2015–2017). Neuro Med Chir (Tokyo). 59 (Suppl):S1–S81. 2019.
|
|
3
|
Maher EA, Furnari FB, Bachoo RM, Rowitch
DH, Louis DN, Cavenee WK and DePinho RA: Malignant glioma: Genetics
and biology of a grave matter. Genes Dev. 15:1311–1333. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pitti RM, Marsters SA, Ruppert S, Donahue
CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2
ligand, a new member of the tumor necrosis factor cytokine family.
J Biol Chem. 271:12687–12690. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Walczak H, Miller RE, Ariail K, Gliniak B,
Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, et al:
Tumoricidal activity of tumor necrosis factor-related
apoptosis-inducing ligand in vivo. Nat Med. 5:157–163. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ashkenazi A, Holland P and Eckhardt SG:
Ligand-based targeting of apoptosis in cancer: The potential of
recombinant human apoptosis ligand 2/tumor necrosis factor-related
apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol.
26:3621–3630. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Naoum GE, Buchsbaum DJ, Tawadros F,
Farooqi A and Arafat WO: Journey of TRAIL from bench to bedside and
its potential role in immuno-oncology. Oncol Rev. 11:3322017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
von Karstedt S, Montinaro A and Walczak H:
Exploring the TRAILs less travelled: TRAIL in cancer biology and
therapy. Nat Rev Cancer. 17:352–366. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Suliman A, Lam A, Datta R and Srivastava
RK: Intracellular mechanisms of TRAIL: Apoptosis through
mitochondrial-dependent and -independent pathways. Oncogene.
20:2122–2133. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nagane M, Huang HJ and Cavenee WK: The
potential of TRAIL for cancer chemotherapy. Apoptosis. 6:191–197.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kuijlen JM, Bremer E, Mooij JJ, den Dunnen
WF and Helfrich W: Review: On TRAIL for malignant glioma therapy?
Neuropathol Appl Neurobiol. 36:168–182. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hawkins CJ: TRAIL and malignant glioma.
Vitam Horm. 67:427–452. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shang Z and Zhang L: Digitoxin increases
sensitivity of glioma stem cells to TRAIL-mediated apoptosis.
Neurosci Lett. 653:19–24. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Khan M, Bi Y, Qazi JI, Fan L and Gao H:
Evodiamine sensitizes U87 glioblastoma cells to TRAIL via the death
receptor pathway. Mol Med Rep. 11:257–262. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Badr CE, Wurdinger T, Nilsson J, Niers JM,
Whalen M, Degterev A and Tannous BA: Lanatoside C sensitizes
glioblastoma cells to tumor necrosis factor-related
apoptosis-inducing ligand and induces an alternative cell death
pathway. Neuro Oncol. 13:1213–1224. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yoon MJ, Kang YJ, Kim IY, Kim EH, Lee JA,
Lim JH, Kwon TK and Choi KS: Monensin, a polyether ionophore
antibiotic, overcomes TRAIL resistance in glioma cells via
endoplasmic reticulum stress, DR5 upregulation and c-FLIP
downregulation. Carcinogenesis. 34:1918–1928. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Calzolari A, Saulle E, De Angelis ML,
Pasquini L, Boe A, Pelacchi F, Ricci-Vitiani L, Baiocchi M and
Testa U: Salinomycin potentiates the cytotoxic effects of TRAIL on
glioblastoma cell lines. PLoS One. 9:e944382014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Borden EC, Sen GC, Uze G, Silverman RH,
Ransohoff RM, Foster GR and Stark GR: Interferons at age 50: Past,
current and future impact on biomedicine. Nat Rev Drug Discov.
6:975–990. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Isaacs A and Lindenmann J: Virus
interference. I. The interferon. Proc R Soc Lond B Biol Sci.
147:258–267. 1957. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vannucchi S, Chiantore MV, Mangino G,
Percario ZA, Affabris E, Fiorucci G and Romeo G: Perspectives in
biomolecular therapeutic intervention in cancer: From the early to
the new strategies with type I interferons. Curr Med Chem.
14:667–679. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoshida J, Kajita Y, Wakabayashi T and
Sugita K: Long-term follow-up results of 175 patients with
malignant glioma: Importance of radical tumor resection and
postoperative adjuvant therapy with interferon, ACNU and radiation.
Acta Neurochir (Wien). 127:55–59. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Watanabe T, Katayama Y, Yoshino A, Komine
C, Yokoyama T and Fukushima T: Treatment of low-grade diffuse
astrocytomas by surgery and human fibroblast interferon without
radiation therapy. J Neurooncol. 61:171–176. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Natsume A, Ishii D, Wakabayashi T, Tsuno
T, Hatano H, Mizuno M and Yoshida J: IFN-beta down-regulates the
expression of DNA repair gene MGMT and sensitizes resistant glioma
cells to temozolomide. Cancer Res. 65:7573–7579. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Watanabe T, Katayama Y, Yoshino A, Fukaya
C and Yamamoto T: Human interferon beta, nimustine hydrochloride,
and radiation therapy in the treatment of newly diagnosed malignant
astrocytomas. J Neurooncol. 72:57–62. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yoshino A, Ogino A, Yachi K, Ohta T,
Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Naruse N and Sano
E: Effect of IFN-beta on human glioma cell lines with temozolomide
resistance. Int J Oncol. 35:139–148. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Der SD, Zhou A, Williams BR and Silverman
RH: Identification of genes differentially regulated by interferon
alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad
Sci USA. 95:15623–15628. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chawla-Sarkar M, Lindner DJ, Liu YF,
Williams BR, Sen GC, Silverman RH and Borden EC: Apoptosis and
interferons: Role of interferon-stimulated genes as mediators of
apoptosis. Apoptosis. 8:237–249. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yoshino A, Ogino A, Yachi K, Ohta T,
Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Naruse N, Sano E
and Tsumoto K: Gene expression profiling predicts response to
temozolomide in malignant gliomas. Int J Oncol. 36:1367–1377. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wischhusen J, Naumann U, Ohgaki H,
Rastinejad F and Weller M: CP-31398, a novel p53-stabilizing agent,
induces p53-dependent and p53-independent glioma cell death.
Oncogene. 22:8233–8245. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Higuchi Y and Hashida M: Pharmacokinetics
of interferon. Clinic All-Round. 52:2499–2505. 2003.(In
Japanese).
|
|
32
|
Soria JC, Márk Z, Zatloukal P, Szima B,
Albert I, Juhász E, Pujol JL, Kozielski J, Baker N, Smethurst D, et
al: Randomized phase II study of dulanermin in combination with
paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell
lung cancer. J Clin Oncol. 29:4442–4451. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cheah CY, Belada D, Fanale MA, Janikova A,
Czucman MS, Flinn IW, Kapp AV, Ashkenazi A, Kelley S, Bray GL, et
al: Dulanermin with rituximab in patients with relapsed indolent
B-cell lymphoma: An open-label phase 1b/2 randomised study. Lancet
Haematol. 2:e166–e174. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ray P, Guha D, Chakraborty J, Banerjee S,
Adhikary A, Chakraborty S, Das T and Sa G: Crocetin exploits
p53-induced death domain (PIDD) and FAS-associated death domain
(FADD) proteins to induce apoptosis in colorectal cancer. Sci Rep.
6:329792016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Edagawa M, Kawauchi J, Hirata M, Goshima
H, Inoue M, Okamoto T, Murakami A, Maehara Y and Kitajima S: Role
of ATF3 for ER stress-induced sensitization of p53-deficient human
colon cancer cells to TRAIL-mediated apoptosis through upregulation
of DR5 by zerumbone and celecoxib. J Biol Chem. 289:21544–21561.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Earel JK Jr, VanOosten RL and Griffith TS:
Histone deacetylase inhibitors modulate the sensitivity of tumor
necrosis factor-related apoptosis-inducing ligand-resistant bladder
tumor cells. Cancer Res. 66:499–507. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu J, Gao Q, Xie T, Liu Y, Luo L, Xu C,
Shen L, Wan F, Lei T and Ye F: Synergistic effect of TRAIL and
irradiation in elimination of glioblastoma stem-like cells. Clin
Exp Med. 18:399–411. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Röhn TA, Wagenknecht B, Roth W, Naumann U,
Gulbins E, Krammer PH, Walczak H and Weller M: CCNU-dependent
potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells
is p53-independent but may involve enhanced cytochrome c release.
Oncogene. 20:4128–4137. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hao C, Beguinot F, Condorelli G, Trencia
A, Van Meir EG, Yong VW, Parney IF, Roa WH and Petruk KC: Induction
and intracellular regulation of tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) mediated apoptosis in human
malignant glioma cells. Cancer Res. 61:1162–1170. 2001.PubMed/NCBI
|
|
41
|
Xiao C, Yang BF, Asadi N, Beguinot F and
Hao C: Tumor necrosis factor-related apoptosis-inducing
ligand-induced death-inducing signaling complex and its modulation
by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem.
277:25020–25025. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rieger AM, Nelson KL, Konowalchuk JD and
Barreda DR: Modified annexin V/propidium iodide apoptosis assay for
accurate assessment of cell death. J Vis Exp. 24:2011.
|
|
43
|
Cohen GM: Caspases: The executioners of
apoptosis. Biochem J. 326:1–16. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Green DR: Apoptotic pathways: Paper wraps
stone blunts scissors. Cell. 102:1–4. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Fulda S and Debatin KM: Extrinsic versus
intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene.
25:4798–4811. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ding L, Yuan C, Wei F, Wang G, Zhang J,
Bellail AC, Zhang Z, Olson JJ and Hao C: Cisplatin restores TRAIL
apoptotic pathway in glioblastoma-derived stem cells through
up-regulation of DR5 and down-regulation of c-FLIP. Cancer Invest.
29:511–520. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wu GS, Burns TF, McDonald ER III, Jiang W,
Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, et al:
KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor
gene. Nat Genet. 17:141–143. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Huang Y, Yang X, Xu T, Kong Q, Zhang Y,
Shen Y, Wei Y, Wang G and Chang KJ: Overcoming resistance to
TRAIL-induced apoptosis in solid tumor cells by simultaneously
targeting death receptors, c-FLIP and IAPs. Int J Oncol.
49:153–163. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Min KJ, Um HJ, Seo SU, Woo SM, Kim S, Park
JW, Lee HS, Kim SH, Choi YH, Lee TJ and Kwon TK: Angelicin
potentiates TRAIL-induced apoptosis in renal carcinoma Caki cells
through activation of caspase 3 and down-regulation of c-FLIP
expression. Drug Dev Res. 79:3–10. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lemke J, von Karstedt S, Abd El Hay M,
Conti A, Arce F, Montinaro A, Papenfuss K, El-Bahrawy MA and
Walczak H: Selective CDK9 inhibition overcomes TRAIL resistance by
concomitant suppression of cFlip and Mcl-1. Cell Death Differ.
21:491–502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Woo SM, Min KJ, Seo BR and Kwon TK: YM155
sensitizes TRAIL-induced apoptosis through cathepsin S-dependent
down-regulation of Mcl-1 and NF-κB-mediated down-regulation of
c-FLIP expression in human renal carcinoma Caki cells. Oncotarget.
7:61520–61532. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Irmler M, Thome M, Hahne M, Schneider P,
Hofmann K, Steiner V, Bodmer JL, Schröter M, Burns K, Mattmann C,
et al: Inhibition of death receptor signals by cellular FLIP.
Nature. 388:190–195. 1997. View
Article : Google Scholar : PubMed/NCBI
|
